Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.

ABSTRACT:

Background

The PD-1-blocking antibody nivolumab persists in patients several weeks after the last infusion. However, no study has systematically evaluated the maximum duration that the antibody persists on T cells or the association between this duration and residual therapeutic efficacy or potential adverse events.

Methods

To define the duration of binding and residual efficacy of nivolumab after discontinuation, we developed a simplified strategy for T cell monitoring and used it to analyze T cells from peripheral blood from 11 non-small cell lung cancer patients previously treated with nivolumab. To determine the suitability of our method for other applications, we compared transcriptome profiles between nivolumab-bound and nivolumab-unbound CD8 T cells. We also applied T

SUBMITTER: Osa A 

PROVIDER: S-EPMC6237460 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature